The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer.
John Marshall
Consultant or Advisory Role - Amgen; Genentech
Honoraria - Amgen; Genentech
Jimmy J. Hwang
No relevant relationships to disclose
Michael J. Pishvaian
No relevant relationships to disclose
Aiwu Ruth He
No relevant relationships to disclose
Louis M. Weiner
No relevant relationships to disclose
Erin K. Sandene
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
Christopher Ryan Heery
No relevant relationships to disclose
Jeffrey Schlom
Research Funding - GlobeImmune
Sue Speyer
Employment or Leadership Position - GlobeImmune
Joni Richman
Employment or Leadership Position - GlobeImmune
John Ferraro
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
Claire Coeshott
Employment or Leadership Position - GlobeImmune
Allen Cohn
Employment or Leadership Position - GlobeImmune
David Apelian
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
Timothy C. Rodell
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
Research Funding - GlobeImmune
Other Remuneration - GlobeImmune